Search results
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Zacks via Yahoo Finance· 1 year agoSanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat...
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Investor's Business Daily· 5 months agoRegeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...
Sanofi Scores A Big Beat As Dupixent Snags The Spotlight, Again
Investor's Business Daily· 2 years agoSanofi stock inched higher Thursday after the Swiss pharma giant beat Wall Street's quarterly views...
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Zacks via Yahoo Finance· 1 year agoThis week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a...
US FDA approves Dupixent to treat younger kids with esophageal condition
Reuters via AOL· 3 months ago(Reuters) -The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to...
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Investor's Business Daily· 1 year agoRegeneron stock surged Friday on stronger-than-expected metrics, though its partner Sanofi posted a...
Sanofi forecasts moderate profit growth on Dupixent demand
Reuters via Yahoo News· 1 year ago(Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for...
Sanofi Raises Profit Guide And Reverses A Drug-Pricing Pitfall
Investor's Business Daily· 2 years agoSanofi stock ended flat Thursday — reversing earlier declines — despite lifting its profit guidance...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 1 month agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
Benzinga via Yahoo Finance· 12 months agoFrench drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in...